3D Systems Corporation (NYSE:DDD) announced that it plans to present at the Stifel 2015 Technology, Internet & Media Conference at The Westin St. Francis in San Francisco, CA on Monday, February 9, 2015 at 11:30 AM PT. On Tuesday shares of 3D Systems Corporation (NYSE:DDD) closed at $28.62. Company’s sales growth for last 5 years was 29.90% and EPS growth for next 5 years is recorded as 21.33%.
The Procter & Gamble Company (NYSE:PG) on 27 January reported second quarter fiscal year 2015 core earnings per share of $1.06 versus $1.15 the prior year. On a currency-neutral basis, core earnings per share increased six percent. Diluted net earnings per share were $0.82, including non-core items which reduced diluted EPS by $0.24 per share. Organic sales grew two percent for the quarter. The Procter & Gamble Company (NYSE:PG) in last trading activity moved up 0.98% to close at $85.95. Company weekly performance is -0.62% while its quarterly performance stands at -0.81%. The Procter & Gamble Company (NYSE:PG) is -7.80% away from its 52 week high.
Pure Cycle Corporation (NASDAQ: PCYO) announces that the Company and High Plains A&M, LLC (“HP”) have reached a comprehensive settlement of all outstanding litigation. On last trading day Pure Cycle Corporation (NASDAQ:PCYO) decreased -0.48% to close at $4.18. Its volatility for the week is 5.09% while volatility for the month is 4.85%. PCYO’s sales growth for past 5 years was 59.50% and its EPS growth for past 5 years was 48.60%. Pure Cycle Corporation (NASDAQ:PCYO) monthly performance is 5.82%.
Reading International (NASDAQ:RDI) Director Douglas James Mceachern bought 6,000 shares of the stock on the open market in a transaction dated Wednesday, January 21st. The shares were purchased at an average cost of $12.01 per share, with a total value of $72,060.00. Reading International, Inc. (NASDAQ:RDI) has 4.90% insider ownership while its institutional ownership stands at 25.20%. In last trading activity company’s stock closed at $12.09.
MediciNova, Inc., (NASDAQ:MNOV) announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of NASH (nonalcoholic steatohepatitis). On last trading day MediciNova Inc. (NASDAQ:MNOV) moved down -1.54% to close at $3.84. Its volatility for the week is 7.50% while volatility for the month is 6.83%. MNOV’s EPS growth for past 5 years was 36.40%. MediciNova Inc. (NASDAQ:MNOV) monthly performance is 16.36%.